The Filing Desk

Orthofix Medical

OFIX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

OFIX · Last close · November 19, 2026
$6.34
Value Orthofix Medical yourself

Orthofix Medical's revenue rose 2.9% to $822 million in fiscal 2025. Its operating margin was −9.9%, up from −10.6% a year earlier. Free cash flow was −$1 million. The diluted share count rose 3.9%.

ORTHOFIX MEDICAL INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001193125-26-065189 Updated
Revenue
$822M
2.9%
Operating margin
−9.9%
0.7 pts
Net income
−$92M
 
Free cash flow
−$1M
 
Return on capital
−11.3%
0.8 pts
Market cap
$261M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Orthofix Medical does

Orthofix is a medical device company based in Lewisville, Texas. It sells products used to treat bone and spine conditions: spinal implants and hardware, bone growth stimulation devices that help bones fuse or heal, limb reconstruction products, bone graft materials called biologics, and a surgical navigation system called 7D FLASH. Its customers are hospitals, ambulatory surgery centers and the surgeons who work in them.

It has two segments, Global Spine and Global Limb Reconstruction, which made up 84% and 16% of its net sales in 2025. Spine includes the bone growth therapies, spinal implants, biologics and navigation technology. It sells much of it worldwide through a network of distributors and sales representatives. It says it competes with many companies, several of which have more financial, manufacturing, marketing and technical resources.

Orthofix was founded in Verona, Italy, in 1980. In January 2023 it acquired SeaSpine in an all-stock merger, which now forms significant parts of its spinal implants, navigation and biologics lines. At December 31, 2025, it had 1,605 employees worldwide, 1,222 of them in the United States.

Its biggest risks, as it describes them

  • Combining the legacy Orthofix and SeaSpine businesses may not deliver the benefits it expects.
  • Hospital consolidation and purchasing groups may push for price cuts or leave it out as a supplier.
  • It competes with larger device makers in an industry with fast technology change.
  • It relies on a limited number of suppliers for some products and parts.
  • Its bone graft products from donated human tissue face supply, regulatory and public-perception risks.
From Orthofix Medical's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2020, earnings per share fell 6.5% a year and net income 5.2% a year, as new shares raised the share count by 5% and diluted each share's earnings. Orthofix Medical then lost money in fiscal 2021, 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments8851338382
Debt incl. finance leases2020114175175
Net debt (negative means net cash)−68−31809293
Net debt to EBITDA−3.2x−2.0x———
Debt to equity0.1x0.1x0.2x0.3x0.4x
Interest coverage−5.5x−9.5x−24.0x−5.0x−4.7x
Current ratio2.5x3.1x2.5x2.6x2.5x
Quick ratio1.8x1.9x1.2x1.4x1.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Orthofix Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Orthofix Medical says to expect

  • Full year 2026: net salesNet sales are now expected to range from $825 million to $830 million, compared with prior guidance of $845 million to $855 million.
  • Full year 2026: non-GAAP adjusted EBITDANon-GAAP adjusted EBITDA guidance is now expected to range from $86 million to $88 million, compared with prior guidance of $95 million to $98 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $4.1 million of Orthofix Medical shares on the open market, and 9 insiders sold $6.6 million, $1,408 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 21, 2026Juniper Investment Company LLC10% ownerSold190,000$8.86$1.7 millionForm 4
Sep 18, 2026Juniper Investment Company LLC10% ownerSold120,000$8.74$1.0 millionForm 4
Sep 1, 2026Patrick FisherPresident, Global Limb ReconSold plan150$9.39$1,408Form 4
Aug 18, 2026Patrick FisherPresident, Global Limb ReconSold1,295$10.09$13,067Form 4
Aug 17, 2026Alexis P Michas10% ownerSold20,000$10.01$200,200Form 4
Aug 14, 2026Alexis P Michas10% ownerSold19,500$10.38$202,410Form 4
Jun 18, 2026Aviva McPherronPres, Global Ops & QualSold3,670$9.38$34,425Form 4
May 22, 2026Juniper Investment Company LLC10% ownerSold242,000$10.70$2.6 millionForm 4
May 7, 2026Engine Jet Capital L.P.10% ownerBought30,000$12.18$365,500Form 4
May 7, 2026John B Henneman IIIDirectorBought5,000$12.26$61,300Form 4
May 6, 2026Engine Jet Capital L.P.10% ownerBought41,946$12.23$513,000Form 4
May 5, 2026Engine Jet Capital L.P.10% ownerBought112,950$11.99$1.4 millionForm 4
The latest 12 of 35 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 95 of 95 of 9
Rule of 4047.9%5.9%2.7%
Altman Z''2.201.651.02
Accruals ratio−15.3%−16.7%−14.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassFailPass
F-score2 of 95 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Orthofix Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Orthofix MedicalFY252.9%−9.9%−0.2%−11.3%—5
Varex ImagingFY254.1%−3.3%2.2%−2.9%—6Compare
AlphatecFY2524.9%−10.8%0.4%−14.3%—5Compare
iRhythmFY2526.2%−7.7%4.6%−12.4%—5Compare
Inspire Medical SystemsFY2513.6%5.6%8.6%14.2%−4.8x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue410434453460407464461747800822
Revenue growth3.4%5.9%4.4%1.5%−11.6%14.2%−0.8%62.1%7.1%2.9%
Gross profit322341356359305350337486546566
Research and development29303335395049807466
Operating income214130−19−6−8−13−139−85−81
Net income3614−282−38−20−151−126−92
Diluted EPS (US$)0.170.340.72−1.510.13−1.95−0.98−4.12−3.30−2.33
Diluted shares (millions)18181919192020373840
Cash flow
Cash from operations593950327418−12−462633
Capital expenditure16151419161821603535
Free cash flow43243613591−33−106−9−1
Dividends paid0000000000
Share buybacks63000000000
Acquisitions004401800000
Stock-based compensation16131922161518363229
Balance sheet at fiscal year end
Cash and short-term investments40817070968851338382
Debt incl. finance leases00021232020114175175
Total assets372405467496526477459925893851
Total liabilities109109131168169140122327390401
Shareholders' equity264297335328357337337599503450
Margins and ratios
Gross margin78.6%78.5%78.7%78.1%74.9%75.3%73.2%65.1%68.3%68.8%
Operating margin5.1%9.4%6.6%−4.1%−1.5%−1.8%−2.9%−18.6%−10.6%−9.9%
Net margin0.8%1.4%3.0%−6.2%0.6%−8.3%−4.3%−20.3%−15.8%−11.2%
Free cash flow margin10.4%5.6%8.0%2.8%14.5%0.1%−7.1%−14.2%−1.1%−0.2%
Rule of 40 (growth + FCF margin)13.8%11.5%12.4%4.4%2.9%14.4%−8.0%47.9%5.9%2.7%
Return on capital4.7%9.3%7.5%−5.5%−1.8%−2.4%−3.6%−22.3%−10.5%−11.3%
Return on equity1.1%2.2%4.4%−8.6%0.7%−11.1%−5.9%−32.4%−22.9%−19.3%
Return on assets0.8%1.6%3.2%−5.9%0.5%−7.7%−4.2%−21.9%−13.9%−10.6%
Net debt to EBITDA−0.9x−1.3x−1.4x−8.2x−3.0x−3.2x−2.0x———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Orthofix Medical's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Orthofix Medical.